Evidence map›Paper›PMID 36245972›Full record

ArticleJournal of oncology2022

APOBEC3B and CD274 as Combined Biomarkers for Predicting Response to Immunotherapy in Urothelial Carcinoma of the Bladder.

Chuanhao Zhang, Zhichao Cheng, Zhe Wang, Genghao Zhao, Yonghui Yuan, Ruoyu Wang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Towards biomarker-driven therapies for urothelial carcinoma.Nature reviews. Clinical oncology · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Chuanhao ZhangGraduate School of Dalian Medical University, Dalian, China.ORCID https://orcid.org/0000-0003-3858-3435
Zhichao ChengGraduate School of Xuzhou Medical University, Xuzhou, China.ORCID https://orcid.org/0000-0001-9348-8946
Zhe WangDepartement of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.ORCID https://orcid.org/0000-0001-7414-4283
Genghao ZhaoGraduate School of Dalian Medical University, Dalian, China.ORCID https://orcid.org/0000-0001-6927-5588
Yonghui YuanCancer Hospital of China Medical University Liaoning Cancer Hospital & Institute, Shenyang, China.ORCID https://orcid.org/0000-0001-8826-6687
Ruoyu WangDepartement of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.ORCID https://orcid.org/0000-0003-3570-1811
Dalian Medical University · CNDalian University · CNLiaoning Cancer Hospital & Institute · CNXuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy has become a promising form of treatment for cancers. There is a need to predict response to immunotherapy accurately. In the UCSC Xena, pan-cancer analysis revealed a positive relationship between APOBEC3B (A3B) and tumor mutational burden (

Identifiers

PMID36245972
PMCPMC9557251
OpenAlexW4297201149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.